Company intelligence / Profile preview
Peak Bio, Inc.
Pleasanton, California, United Statespeak-bio.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
01
Overview
Lead program PHP‑303 reached Phase II readiness for AATD. The company also developed a proprietary ADC platform targeting oncology indications. After merging with Akari Therapeutics in late 2024, the combined entity continues development of these assets alongside new autoimmune/inflammatory disease programs.
- Therapeutic areas
- OncologyPulmonologyRare DiseasesImmunology
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Peak Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peak Bio, Inc..